{"id":"NCT01969721","sponsor":"Boehringer Ingelheim","briefTitle":"Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients","officialTitle":"Randomized, Double-blind, Double-dummy, Active-controlled, 4 Period Complete Cross-over Study to Compare the Effect on Lung Function of 6 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat® Inhaler vs. 6 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Accuhaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2015-01","completion":"2015-02","firstPosted":"2013-10-25","resultsPosted":"2016-02-12","lastUpdate":"2016-02-12"},"enrollment":229,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"fluticasone propionate","otherNames":[]},{"type":"DRUG","name":"salmeterol","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]},{"type":"DRUG","name":"olodaterol","otherNames":[]},{"type":"DRUG","name":"olodaterol","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]},{"type":"DRUG","name":"fluticasone propionate","otherNames":[]},{"type":"DRUG","name":"salmeterol","otherNames":[]}],"arms":[{"label":"T+O FDC dosage 1","type":"EXPERIMENTAL"},{"label":"T+O FDC dosage 2","type":"EXPERIMENTAL"},{"label":"ICS/LABA FDC Dosage 1","type":"ACTIVE_COMPARATOR"},{"label":"ICS/LABA FDC Dosage 2","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of the trial is to compare the lung function profile of once daily treatment with tiotropium+olodaterol FDC \\[2.5/ 5µg and 5/ 5µg\\] delivered by the RESPIMAT with the lung function profile of twice daily treatment with fluticasone propionate+salmeterol FDC \\[250/50µg and 500/50µg\\] delivered by the Accuhaler® after 6 weeks of treatment.","primaryOutcome":{"measure":"FEV1 AUC (0-12h) Change From Patient Baseline After 6 Weeks of Treatment","timeFrame":"Baseline and 6 weeks.","effectByArm":[{"arm":"T+O 2.5/5 / F+S Placebo","deltaMin":0.295,"sd":0.014},{"arm":"T+O 5/5 / F+S Placebo","deltaMin":0.317,"sd":0.014},{"arm":"F+S 250/50 / T+O Placebo","deltaMin":0.192,"sd":0.015},{"arm":"F+S 500/50 / T+O Placebo","deltaMin":0.188,"sd":0.014}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":29,"countries":["Belgium","Czechia","Denmark","Germany","Hungary","Netherlands","Spain","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":215},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis"]}}